VR Logo

Arrowhead Pharmaceuticals Inc. (ARWR) download report


Healthcare | Biotechnology & Pharma Research

Arrowhead Pharmaceuticals Inc. (ARWR) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.

IPO Date: 16-Jun-1993

CEO, Pres & Director: Dr. Christopher R. Anzalone Ph.D.

Chief Financial Officer: Mr. Kenneth A. Myszkowski

Listing: NASDAQ: ARWR

Country: United States

Headquarters: Pasadena, CA

Website: https://arrowheadpharma.com

Key Facts

Market cap: $4,864.82 Mln

Revenue (TTM): $249.94 Mln

Earnings (TTM): $-153.93 Mln

Cash: $416.50 Mln

Total Debt: $81.11 Mln

Insider's Holding: 2.65%

Liquidity: Low

52 Week range: $26.81 - 84.83

Shares outstanding: 105,736,000

10 Years Aggregate:

  • CFO: $-22.22 Mln
  • EBITDA: $-484.25 Mln
  • Net Profit: $-530.82 Mln

Stock Performance

Time Period Arrowhead Pharmaceuticals (ARWR) S&P BSE Sensex S&P Small-Cap 600
YTD-29.861.03-10.95
1 month10.278.638.86
3 months25.957.333.26
1 Year-28.238.43-7.97
3 Years17.3817.0610.60
5 Years86.8812.777.87
10 Years28.8412.8310.72
As on 08-Aug-2022
Year Arrowhead Pharmaceuticals (ARWR) S&P Small-Cap 600 S&P BSE Sensex
2021-13.5925.2721.99
202020.979.5715.75
2019410.7120.8614.38
2018235.27-9.705.87
2017137.4211.7327.91
2016-74.8024.741.95
2015-16.67-3.36-5.03